Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 5/20 | 0.44 |
| ▸ | PYGM | P11217 | 5/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032026 | 0.81 | CREBBP (0.51) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15414847 | 0.80 | TDP2 (0.42) | NPC1MAPK14MAPTCRBNALDH1A1 | |
| SCHEMBL23188830 | 0.79 | NPC1 (0.43) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2214341 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1270022 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13904707 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12598688 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2608569 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22048708 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL859143 | 0.79 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-5374721-A | Benzo-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
| WO-1994018169-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5310737-A | Benzo-fused lactams that promote the release of growth hormone | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1994007486-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994005634-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5284841-A | Benzo-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5283241-A | Animal growth regulators | MERCK & CO., INC. (US) | 1994-02-01 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | NPC1 1136/4885MAPK13 316/4885MAPK12 375/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.